QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
QIAGEN’s leading TB blood test, QuantiFERON-TB Gold Plus, remains crucial in detecting latent tuberculosis infection, aiding in breaking the cycle of disease transmission. QIAGEN’s TB Tests in ...
Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.
Interferon-Gamma IGRAs, such as the QuantiFERON-TB Gold test and the T-SPOT.TB test, measure the release of interferon-gamma by T-cells in response to TB antigens. Unlike TST, IGRAs are not ...
T-Spot Lab Test, or Quantiferon Gold Lab Test. These health forms are required before moving into residence halls and starting classes at Keene State College. Health forms are due on June 1, 2022 for ...
covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection. "Protecting our intellectual property is essential to ensuring continued innovation in infectious ...